Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more
Day One Biopharmaceuticals Inc (DAWN) - Net Assets
Latest net assets as of September 2025: $450.87 Million USD
Based on the latest financial reports, Day One Biopharmaceuticals Inc (DAWN) has net assets worth $450.87 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($513.78 Million) and total liabilities ($62.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $450.87 Million |
| % of Total Assets | 87.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1056.79% |
| 10-Year Change | N/A |
| Growth Volatility | 227.54 |
Day One Biopharmaceuticals Inc - Net Assets Trend (2019–2024)
This chart illustrates how Day One Biopharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Day One Biopharmaceuticals Inc (2019–2024)
The table below shows the annual net assets of Day One Biopharmaceuticals Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $502.75 Million | +45.08% |
| 2023-12-31 | $346.54 Million | +4.37% |
| 2022-12-31 | $332.04 Million | +18.10% |
| 2021-12-31 | $281.15 Million | +546.90% |
| 2020-12-31 | $43.46 Million | +938.04% |
| 2019-12-31 | $-5.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Day One Biopharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54129700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.00% |
| Other Comprehensive Income | $84.00K | 0.02% |
| Other Components | $1.06 Billion | 210.19% |
| Total Equity | $502.75 Million | 100.00% |
Day One Biopharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Day One Biopharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FIBRA Macquarie México
PINK:DBMBF
|
$1.13 Billion |
|
FORCE MOTORS LTD
NSE:FORCEMOT
|
$1.13 Billion |
|
Cencosud Shopping SA
SN:CENCOMALLS
|
$1.13 Billion |
|
State Grid Yingda Co Ltd
SHG:600517
|
$1.13 Billion |
|
THAI LIFE INSURANCE PUBLIC COMPANY
BK:TLI-R
|
$1.13 Billion |
|
Visual Photonics Epitaxy Co Ltd
TW:2455
|
$1.13 Billion |
|
The Bank of East Asia Limited
PINK:BKEAF
|
$1.13 Billion |
|
Ladder Capital Corp Class A
NYSE:LADR
|
$1.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Day One Biopharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 346,540,000 to 502,751,000, a change of 156,211,000 (45.1%).
- Net loss of 95,496,000 reduced equity.
- Share repurchases of 25,114,000 reduced equity.
- New share issuances of 178,177,000 increased equity.
- Other comprehensive income increased equity by 75,000.
- Other factors increased equity by 98,569,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-95.50 Million | -18.99% |
| Share Repurchases | $25.11 Million | -5.0% |
| Share Issuances | $178.18 Million | +35.44% |
| Other Comprehensive Income | $75.00K | +0.01% |
| Other Changes | $98.57 Million | +19.61% |
| Total Change | $- | 45.08% |
Book Value vs Market Value Analysis
This analysis compares Day One Biopharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.17 | $21.29 | x |
| 2020-12-31 | $0.61 | $21.29 | x |
| 2021-12-31 | $4.54 | $21.29 | x |
| 2022-12-31 | $5.07 | $21.29 | x |
| 2023-12-31 | $4.34 | $21.29 | x |
| 2024-12-31 | $5.37 | $21.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Day One Biopharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -72.81%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.16x
- Recent ROE (-18.99%) is above the historical average (-40.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.57 Million |
| 2020 | -107.28% | 0.00% | 0.00x | 1.21x | $-44.28 Million |
| 2021 | -25.06% | 0.00% | 0.00x | 1.03x | $-98.56 Million |
| 2022 | -39.81% | 0.00% | 0.00x | 1.05x | $-165.38 Million |
| 2023 | -54.52% | 0.00% | 0.00x | 1.09x | $-223.57 Million |
| 2024 | -18.99% | -72.81% | 0.23x | 1.16x | $-145.77 Million |
Industry Comparison
This section compares Day One Biopharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Day One Biopharmaceuticals Inc (DAWN) | $450.87 Million | 0.00% | 0.14x | $1.13 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |